Modulation of Mast Cell Proliferative and Inflammatory Responses by Leukotriene D4 and Stem Cell Factor Signaling Interactions
暂无分享,去创建一个
S. Paruchuri | Farai C Gombedza | C. Thodeti | Nosayba Al-Azzam | Ernest Duah | V. Kondeti | Farai Gombedza
[1] S. Paruchuri,et al. Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors , 2013, Scientific Reports.
[2] S. Paruchuri,et al. Differential Regulation of Cysteinyl Leukotriene Receptor Signaling by Protein Kinase C in Human Mast Cells , 2013, PloS one.
[3] G. Bandara,et al. Prevention of F‐actin assembly switches the response to SCF from chemotaxis to degranulation in human mast cells , 2013, European journal of immunology.
[4] E. Hahn,et al. The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis. , 2011, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[5] J. Steinke,et al. Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI. , 2011, The Journal of allergy and clinical immunology.
[6] S. Paruchuri,et al. Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptor , 2009, The Journal of experimental medicine.
[7] A. Butte,et al. Wiskott-Aldrich syndrome protein is an effector of Kit signaling. , 2008, Blood.
[8] J. Plutzky,et al. Leukotriene E4 Activates Peroxisome Proliferator-activated Receptor γ and Induces Prostaglandin D2 Generation by Human Mast Cells* , 2008, Journal of Biological Chemistry.
[9] Shoko Iwaki,et al. Concurrent Inhibition of Kit- and FcϵRI-Mediated Signaling: Coordinated Suppression of Mast Cell Activation , 2008, Journal of Pharmacology and Experimental Therapeutics.
[10] E. Matsui,et al. Cysteinyl Leukotrienes Regulate Th2 Cell-Dependent Pulmonary Inflammation , 2007, Pediatrics.
[11] D. Metcalfe,et al. Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation. , 2007, Inflammation & allergy drug targets.
[12] M. Tsai,et al. Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. , 2006, Current opinion in immunology.
[13] Yongfeng Jiang,et al. Cutting Edge: Interleukin 4-Dependent Mast Cell Proliferation Requires Autocrine/Intracrine Cysteinyl Leukotriene-Induced Signaling1 , 2006, The Journal of Immunology.
[14] Shoko Iwaki,et al. Adaptive and innate immune reactions regulating mast cell activation: from receptor-mediated signaling to responses. , 2006, Immunology and allergy clinics of North America.
[15] J. Boyce,et al. Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. , 2006, The Journal of allergy and clinical immunology.
[16] D. Friend,et al. Cysteinyl Leukotrienes Regulate Th2 Cell-Dependent Pulmonary Inflammation1 , 2006, The Journal of Immunology.
[17] Christine Tkaczyk,et al. Integrated signalling pathways for mast-cell activation , 2006, Nature Reviews Immunology.
[18] G. Nilsson,et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. , 2005, Blood.
[19] P. Finan,et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response , 2004, Nature.
[20] D. Metcalfe,et al. Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. , 2004, Blood.
[21] Y. Kanaoka,et al. Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory Responses1 , 2004, The Journal of Immunology.
[22] K. Austen,et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] D. Metcalfe,et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. , 2003, Leukemia research.
[24] Calman Prussin,et al. IgE, mast cells, basophils, and eosinophils. , 2003, The Journal of allergy and clinical immunology.
[25] D. Golden,et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; Activation following aggregation of FcεRI and FcγRI , 2003 .
[26] B. Hallberg,et al. Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells. , 2002, Journal of cell science.
[27] K. Austen,et al. Cysteinyl Leukotrienes and Uridine Diphosphate Induce Cytokine Generation by Human Mast Cells Through an Interleukin 4–regulated Pathway that Is Inhibited by Leukotriene Receptor Antagonists , 2002, The Journal of experimental medicine.
[28] K. Austen,et al. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[29] C. Hogaboam,et al. SCF-induced airway hyperreactivity is dependent on leukotriene production. , 2001, American journal of physiology. Lung cellular and molecular physiology.
[30] J. Wedemeyer,et al. Roles of mast cells and basophils in innate and acquired immunity. , 2000, Current opinion in immunology.
[31] Jilly F. Evans,et al. Characterization of the Human Cysteinyl Leukotriene 2 Receptor* , 2000, The Journal of Biological Chemistry.
[32] B. Foster,et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). , 1999, Blood.
[33] Jilly F. Evans,et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor , 1999, Nature.
[34] C. Hogaboam,et al. Stem cell factor-induced airway hyperreactivity in allergic and normal mice. , 1999, The American journal of pathology.
[35] C. Heldin,et al. Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. , 1994, The Journal of biological chemistry.
[36] M. Tsai,et al. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. , 1994, The American journal of pathology.
[37] C. Heldin,et al. Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. , 1993, The EMBO journal.
[38] M. Tsai,et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[39] E. R. Mcfadden,et al. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. , 1987, The American review of respiratory disease.
[40] G. Bandara,et al. Activation Phenotype Stem Cell Factor Programs the Mast Cell , 2012 .
[41] S. Paruchuri,et al. Leukotriene E 4 – induced pulmonary inflammation is mediated by the P 2 Y 12 receptor , 2009 .
[42] Shoko Iwaki,et al. Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. , 2008, The Journal of pharmacology and experimental therapeutics.
[43] Y. Okayama,et al. Development, migration, and survival of mast cells , 2006, Immunologic research.
[44] D. Metcalfe,et al. 5. IgE, mast cells, basophils, and eosinophils. , 2006, The Journal of allergy and clinical immunology.
[45] J. Bienenstock,et al. Mast cells , 2004, Springer Seminars in Immunopathology.
[46] M. Tsai,et al. Regulation of mouse and human mast cell development, survival and function by stem cell factor, the ligand for the c-kit receptor. , 1995, International archives of allergy and immunology.
[47] J. D. de Jongste,et al. Leukotrienes and airway responses. , 1988, The American review of respiratory disease.